Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307295435> ?p ?o ?g. }
- W4307295435 endingPage "122332" @default.
- W4307295435 startingPage "122332" @default.
- W4307295435 abstract "Currently, reducing particle size or preparing drugs into amorphous forms are widely used methods to improve the solubility and dissolution rate of insoluble drugs. The purpose of this study was to prepare nimodipine amorphous nanopowder (NMD-NAP) using nimodipine (NMD) as a model drug to increase the solubility and dissolution rate of insoluble drugs by the combined effect of reducing the particle size and preparing the drug into an amorphous form. The NMD-NAP was successfully prepared by quenching cooling combined with wet milling and spray drying. The prepared NMD-NAP was shown to have good redispersibility by particle size analysis. The shapeof NMD-NAP was characterized by SEM and AFM, showing a spherical or spheroidal structure. The results of PLM, DSC, XRD, and FT-IR indicated that the drug existed in an amorphous form. The dissolution study showed that the dissolution rate of NMD in NMD-NAP was improved about 5 times that of pure NMD and 3 times that of nimodipine nanocrystalline (NMD-NC), indicating the combination of nano size and amorphous form produced a synergistic effect that could significantly increase the dissolution rate of NMD. Due to the significantly improved solubility and good industrial feasibility of the prepared NMD-NAP, the preparation of insoluble drugs into amorphous nanopowders is an effective method to improve the solubility of insoluble drugs and has good application prospects." @default.
- W4307295435 created "2022-10-31" @default.
- W4307295435 creator A5001554559 @default.
- W4307295435 creator A5009374812 @default.
- W4307295435 creator A5012773578 @default.
- W4307295435 creator A5023406954 @default.
- W4307295435 creator A5025212717 @default.
- W4307295435 creator A5048220008 @default.
- W4307295435 creator A5048473316 @default.
- W4307295435 creator A5050080798 @default.
- W4307295435 creator A5071773009 @default.
- W4307295435 date "2022-11-01" @default.
- W4307295435 modified "2023-10-06" @default.
- W4307295435 title "Characterization of nimodipine amorphous nanopowder prepared by quenching cooling combined with wet milling and spray drying" @default.
- W4307295435 cites W1585018972 @default.
- W4307295435 cites W1853947313 @default.
- W4307295435 cites W1965096889 @default.
- W4307295435 cites W1972376417 @default.
- W4307295435 cites W1973721531 @default.
- W4307295435 cites W1980614673 @default.
- W4307295435 cites W1980615171 @default.
- W4307295435 cites W1983162648 @default.
- W4307295435 cites W1992456610 @default.
- W4307295435 cites W1993201496 @default.
- W4307295435 cites W1997870627 @default.
- W4307295435 cites W1999527241 @default.
- W4307295435 cites W2005382186 @default.
- W4307295435 cites W2011115123 @default.
- W4307295435 cites W2011530145 @default.
- W4307295435 cites W2012528272 @default.
- W4307295435 cites W2026930707 @default.
- W4307295435 cites W2028883574 @default.
- W4307295435 cites W2031158522 @default.
- W4307295435 cites W2031641726 @default.
- W4307295435 cites W2044146593 @default.
- W4307295435 cites W2044829159 @default.
- W4307295435 cites W2049887523 @default.
- W4307295435 cites W2054260281 @default.
- W4307295435 cites W205849754 @default.
- W4307295435 cites W2063435985 @default.
- W4307295435 cites W2067507455 @default.
- W4307295435 cites W2075179133 @default.
- W4307295435 cites W2077781847 @default.
- W4307295435 cites W2089305988 @default.
- W4307295435 cites W2117753715 @default.
- W4307295435 cites W2120826143 @default.
- W4307295435 cites W2121629091 @default.
- W4307295435 cites W2124363887 @default.
- W4307295435 cites W2157283424 @default.
- W4307295435 cites W2159341782 @default.
- W4307295435 cites W2169796533 @default.
- W4307295435 cites W2191436776 @default.
- W4307295435 cites W2199144780 @default.
- W4307295435 cites W2237126041 @default.
- W4307295435 cites W2275944058 @default.
- W4307295435 cites W2332573263 @default.
- W4307295435 cites W2517074874 @default.
- W4307295435 cites W2548150499 @default.
- W4307295435 cites W2587005405 @default.
- W4307295435 cites W2591211259 @default.
- W4307295435 cites W2618686510 @default.
- W4307295435 cites W2742797455 @default.
- W4307295435 cites W2766613007 @default.
- W4307295435 cites W2767999118 @default.
- W4307295435 cites W2789026651 @default.
- W4307295435 cites W2793899084 @default.
- W4307295435 cites W2796318978 @default.
- W4307295435 cites W2897195799 @default.
- W4307295435 cites W2909971603 @default.
- W4307295435 cites W2913214048 @default.
- W4307295435 cites W2982582908 @default.
- W4307295435 cites W3045040003 @default.
- W4307295435 cites W3169596185 @default.
- W4307295435 cites W3210769765 @default.
- W4307295435 cites W4200234022 @default.
- W4307295435 cites W4210982805 @default.
- W4307295435 doi "https://doi.org/10.1016/j.ijpharm.2022.122332" @default.
- W4307295435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36283641" @default.
- W4307295435 hasPublicationYear "2022" @default.
- W4307295435 type Work @default.
- W4307295435 citedByCount "0" @default.
- W4307295435 crossrefType "journal-article" @default.
- W4307295435 hasAuthorship W4307295435A5001554559 @default.
- W4307295435 hasAuthorship W4307295435A5009374812 @default.
- W4307295435 hasAuthorship W4307295435A5012773578 @default.
- W4307295435 hasAuthorship W4307295435A5023406954 @default.
- W4307295435 hasAuthorship W4307295435A5025212717 @default.
- W4307295435 hasAuthorship W4307295435A5048220008 @default.
- W4307295435 hasAuthorship W4307295435A5048473316 @default.
- W4307295435 hasAuthorship W4307295435A5050080798 @default.
- W4307295435 hasAuthorship W4307295435A5071773009 @default.
- W4307295435 hasConcept C121332964 @default.
- W4307295435 hasConcept C121745418 @default.
- W4307295435 hasConcept C127413603 @default.
- W4307295435 hasConcept C140676511 @default.
- W4307295435 hasConcept C155574463 @default.
- W4307295435 hasConcept C171250308 @default.
- W4307295435 hasConcept C178790620 @default.